个人中心 - 老虎社区

Bobana

IP属地：未知

帖子 · 3帖子 · 3
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- BobanaBobana
  ·2021-11-07
  Demand for vaccine and COVID pills would continue until world population builds immunity against COVID-19. It is gonna take a few years.
  非常抱歉，此主贴已删除
  1,514 评论
  1
  分享
  举报
- BobanaBobana
  ·2021-11-07
  As population builds immunity, reliance on vaccine and COVID pills should taper off. However, it is gonna take a few years before world population is immune to COVID.
  非常抱歉，此主贴已删除
  941 1
  1
  分享
  举报
- BobanaBobana
  ·2021-11-03
  It’s about time…
  Pfizer's Covid-19 vaccine could break sales records again next year
  WASHINGTON (NYTIMES) - With its coronavirus vaccine on track this year to generate the biggest singl
  Pfizer's Covid-19 vaccine could break sales records again next year
  1,003 评论
  2
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4090131053814620","uuid":"4090131053814620","gmtCreate":1627027990777,"gmtModify":1632371747361,"name":"Bobana","pinyin":"bobana","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/7788a631e9c1ee863fe6497deb7b9367","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":9,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":845109448,"gmtCreate":1636295166081,"gmtModify":1636296904309,"author":{"id":"4090131053814620","authorId":"4090131053814620","name":"Bobana","avatar":"https://static.tigerbbs.com/7788a631e9c1ee863fe6497deb7b9367","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090131053814620","authorIdStr":"4090131053814620"},"themes":[],"htmlText":"Demand for&nbsp;vaccine and COVID pills would continue until world population builds immunity against COVID-19. It is gonna take a few years.","listText":"Demand for&nbsp;vaccine and COVID pills would continue until world population builds immunity against COVID-19. It is gonna take a few years.","text":"Demand for vaccine and COVID pills would continue until world population builds immunity against COVID-19. It is gonna take a few years.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845109448","repostId":"2181742241","repostType":4,"isVote":1,"tweetType":1,"viewCount":1514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845100112,"gmtCreate":1636294923046,"gmtModify":1636296903886,"author":{"id":"4090131053814620","authorId":"4090131053814620","name":"Bobana","avatar":"https://static.tigerbbs.com/7788a631e9c1ee863fe6497deb7b9367","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090131053814620","authorIdStr":"4090131053814620"},"themes":[],"htmlText":"As population builds immunity, reliance on vaccine and COVID pills should taper off. However, it&nbsp;is gonna take a few years before world&nbsp;population is immune to COVID.","listText":"As population builds immunity, reliance on vaccine and COVID pills should taper off. However, it&nbsp;is gonna take a few years before world&nbsp;population is immune to COVID.","text":"As population builds immunity, reliance on vaccine and COVID pills should taper off. However, it is gonna take a few years before world population is immune to COVID.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845100112","repostId":"2181742241","repostType":4,"isVote":1,"tweetType":1,"viewCount":941,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841712022,"gmtCreate":1635942582478,"gmtModify":1635942582644,"author":{"id":"4090131053814620","authorId":"4090131053814620","name":"Bobana","avatar":"https://static.tigerbbs.com/7788a631e9c1ee863fe6497deb7b9367","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090131053814620","authorIdStr":"4090131053814620"},"themes":[],"htmlText":"It’s about time…","listText":"It’s about time…","text":"It’s about time…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841712022","repostId":"2180731902","repostType":4,"repost":{"id":"2180731902","kind":"news","pubTimestamp":1635907288,"share":"https://www.laohu8.com/m/news/2180731902?lang=&edition=full","pubTime":"2021-11-03 10:41","market":"us","language":"en","title":"Pfizer's Covid-19 vaccine could break sales records again next year","url":"https://stock-news.laohu8.com/highlight/detail?id=2180731902","media":"The Straits Times","summary":"WASHINGTON (NYTIMES) - With its coronavirus vaccine on track this year to generate the biggest singl","content":"<div>\n<p>WASHINGTON (NYTIMES) - With its coronavirus vaccine on track this year to generate the biggest single-year sales ever for a medical product, Pfizer on Tuesday (Nov 2) disclosed revenue projections ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizers-covid-19-vaccine-could-break-sales-records-again-next-year\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer's Covid-19 vaccine could break sales records again next year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer's Covid-19 vaccine could break sales records again next year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 10:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/pfizers-covid-19-vaccine-could-break-sales-records-again-next-year><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (NYTIMES) - With its coronavirus vaccine on track this year to generate the biggest single-year sales ever for a medical product, Pfizer on Tuesday (Nov 2) disclosed revenue projections ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizers-covid-19-vaccine-could-break-sales-records-again-next-year\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://www.straitstimes.com/world/united-states/pfizers-covid-19-vaccine-could-break-sales-records-again-next-year","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180731902","content_text":"WASHINGTON (NYTIMES) - With its coronavirus vaccine on track this year to generate the biggest single-year sales ever for a medical product, Pfizer on Tuesday (Nov 2) disclosed revenue projections indicating that the shot will likely beat that record or come close in 2022.\nThe company said while reporting its third quarter earnings that it expects its vaccine to bring in US$36 billion (S$49 billion) in revenue this year.\nPfizer said it has already reached supply deals worth US$29 billion in revenue for its vaccine next year, covering 1.7 billion shots it has already committed to countries around the world.\nBillions more in sales are likely to come as the company reaches more deals to sell to governments the 4 billion shots it expects to produce next year.\nThe company's CEO, Dr Albert Bourla, told analysts Tuesday that most of the company's negotiations are with high- and upper-middle-income countries.\nHe said he was concerned that poorer countries and their proxies were not lining up to place orders.\n\"I don't want to reach a level that again the low- and middle-income countries will be behind in their deliveries because they didn't place their orders,\" he said.\nPfizer says it is selling shots for poorer countries at discounted prices, but many of the world's poorest countries cannot afford to buy doses directly.\nThey have depended on donations from the United States and other wealthy countries, and on supply from Covax, the United Nations programme to vaccinate the globe.\nThere remain stark differences in vaccine access: Worldwide, about 75 per cent of all shots that have gone into arms have been administered in high- and upper-middle-income countries, according to the Our World in Data project at the University of Oxford. Only 0.6 per cent of doses have been administered in low-income countries.\nThe enormous sales figures will translate into billions in profits for Pfizer. The company, which must split its vaccine revenue with development partner BioNTech, said that it expects its profit margins on the vaccine will be in the high 20 per cent range next year, the same margin it projected this year.\nThe doses that will be delivered next year include booster shots, mostly for wealthier countries, and primary immunisations, with an emphasis on second doses, for poorer countries.\nA small chunk of the doses will be given to children. The company won authorisation last week for its vaccine to be given in the United States to children between the ages of 5 and 11.\nAn advisory panel to the Centres for Disease Control and Prevention voted unanimously Tuesday to recommend paediatric doses for that age group, and if the director signs off, children could begin receiving it this week.\nPfizer expects to have initial data from its studies evaluating its vaccine in children between the ages of 2 and 4 by the end of December and in children between the ages of six months and 1 by the end of March, the company's research chief, Dr Mikael Dolsten, told analysts on Tuesday.\nPfizer could get another revenue boost next year from an antiviral pill it is developing for high-risk Covid-19 patients early in their infections. Results are expected within the next few months from a key clinical trial evaluating whether the drug can cut the risk of hospitalisations and death.\nA Pfizer executive, Angela Hwang, said the company sees a market of up to 150 million people for the pill. She called it a \"durable opportunity,\" saying that governments may be interested in stockpiling the drug.\nA rival pill from Merck, known as molnupiravir, has already been shown to halve the risk of hospitalisation in similar patients. Merck said last week that it expects molnupiravir to generate between US$5 billion and US$7 billion in revenue globally through the end of next year.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}